X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Elder Pharma with Orchid Chemicals - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

ELDER PHARMA vs ORCHID PHARMA LTD - Comparison Results

ORCHID PHARMA LTD 
   Change

Orchid Chemicals & Pharmaceuticals Ltd. (Orchid) is today a globally recognized, integrated pharmaceutical company with core competencies in the development and manufacture of Active Pharmaceutical Ingredients (APIs) and Finished Dosage Forms as well... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    ELDER PHARMA ORCHID PHARMA LTD ELDER PHARMA/
ORCHID PHARMA LTD
 
P/E (TTM) x -0.2 -0.5 - View Chart
P/BV x 0.1 0.4 27.0% View Chart
Dividend Yield % 0.0 0.0 -  

Financials

 ELDER PHARMA   ORCHID PHARMA LTD
EQUITY SHARE DATA
    ELDER PHARMA
Jun-14
ORCHID PHARMA LTD
Sep-13
ELDER PHARMA/
ORCHID PHARMA LTD
5-Yr Chart
Click to enlarge
High Rs380194 195.9%   
Low Rs18835 537.1%   
Sales per share (Unadj.) Rs491.2276.5 177.7%  
Earnings per share (Unadj.) Rs-3.2-79.2 4.0%  
Cash flow per share (Unadj.) Rs14.4-43.5 -33.2%  
Dividends per share (Unadj.) Rs00-  
Dividend yield (eoy) %00-  
Book value per share (Unadj.) Rs376.553.9 698.0%  
Shares outstanding (eoy) m20.5470.45 29.2%   
Bonus/Rights/Conversions -ESOP-  
Price / Sales ratio x0.60.4 139.6%   
Avg P/E ratio x-89.3-1.4 6,175.1%  
P/CF ratio (eoy) x19.7-2.6 -748.0%  
Price / Book Value ratio x0.82.1 35.5%  
Dividend payout %00-   
Avg Mkt Cap Rs m5,8338,067 72.3%   
No. of employees `000NA2.8 0.0%   
Total wages/salary Rs m2,1792,527 86.2%   
Avg. sales/employee Rs ThNM6,956.1-  
Avg. wages/employee Rs ThNM902.5-  
Avg. net profit/employee Rs ThNM-1,993.0-  
INCOME DATA
Net Sales Rs m10,08919,477 51.8%  
Other income Rs m257407 63.0%   
Total revenues Rs m10,34619,884 52.0%   
Gross profit Rs m-7921,103 -71.8%  
Depreciation Rs m3612,519 14.3%   
Interest Rs m2,7565,227 52.7%   
Profit before tax Rs m-3,653-6,236 58.6%   
Minority Interest Rs m020 0.0%   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m3,713511 726.6%   
Tax Rs m125-125 -100.0%   
Profit after tax Rs m-65-5,580 1.2%  
Gross profit margin %-7.85.7 -138.7%  
Effective tax rate %-3.42.0 -170.7%   
Net profit margin %-0.6-28.7 2.3%  
BALANCE SHEET DATA
Current assets Rs m9,24011,014 83.9%   
Current liabilities Rs m9,99832,060 31.2%   
Net working cap to sales %-7.5-108.1 7.0%  
Current ratio x0.90.3 269.0%  
Inventory Days Days4695 48.8%  
Debtors Days Days6034 178.6%  
Net fixed assets Rs m10,12429,440 34.4%   
Share capital Rs m206705 29.2%   
"Free" reserves Rs m5,5822,043 273.3%   
Net worth Rs m7,7343,800 203.5%   
Long term debt Rs m4,8899,018 54.2%   
Total assets Rs m22,88246,510 49.2%  
Interest coverage x-0.3-0.2 168.4%   
Debt to equity ratio x0.62.4 26.6%  
Sales to assets ratio x0.40.4 105.3%   
Return on assets %11.8-0.8 -1,547.3%  
Return on equity %-0.8-146.9 0.6%  
Return on capital %22.3-3.7 -597.4%  
Exports to sales %3.037.9 8.0%   
Imports to sales %0.422.6 1.9%   
Exports (fob) Rs m3077,378 4.2%   
Imports (cif) Rs m434,406 1.0%   
Fx inflow Rs m3077,513 4.1%   
Fx outflow Rs m1255,649 2.2%   
Net fx Rs m1811,865 9.7%   
CASH FLOW
From Operations Rs m11,7541,682 698.9%  
From Investments Rs m-561-9,860 5.7%  
From Financial Activity Rs m-6,7626,644 -101.8%  
Net Cashflow Rs m4,432-1,535 -288.7%  

Share Holding

Indian Promoters % 39.6 32.3 122.6%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 7.5 4.6 163.0%  
FIIs % 16.8 3.3 509.1%  
ADR/GDR % 0.0 4.6 -  
Free float % 36.1 55.3 65.3%  
Shareholders   16,479 84,811 19.4%  
Pledged promoter(s) holding % 77.6 54.9 141.2%  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare ELDER PHARMA With:   STERLING BIOTECH  SANOFI INDIA  ALKEM LABORATORIES  SHASUN PHARMA  NOVARTIS  

Compare ELDER PHARMA With:   MYLAN (US)  ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Indian Indices Trade Strong; Metal, Pharma Stocks Lead Gains(01:30 pm)

After opening the day in green, share markets in India have continued the momentum and are presently trading above the dotted line.

Related Views on News

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

Biocon: US Pricing Pressure Takes Toll (Quarterly Results Update - Detailed)

Feb 2, 2018

Pricing pressure in the US and costs of the Malaysian facility hit Biocon's profits in the third quarter.

Shalby Ltd. (IPO)

Dec 2, 2017

Should you subscribe to the IPO of Shalby Ltd?

More Views on News

Most Popular

The Foundation for Sensex 100,000 is Laid(The 5 Minute Wrapup)

Feb 17, 2018

Top three reasons for Tanushree's presentation at Equitymaster Conference to be centered around a possible 30% correction.

India's Rs 1,66,276 Crore Problem(Vivek Kaul's Diary)

Feb 15, 2018

That's the loss, the government owned public sector enterprises are expected to make this year.

The Big Gamble(The Honest Truth)

Feb 15, 2018

Once you accept the fact that elections are round the corner and that this budget is geared to reach a 40% target, everything makes sense.

How I Beat the Index by 2x... And Why I Believe This Could Happen Again(Smart Contrarian)

Feb 12, 2018

Will Microcap Millionaires be able to replicate its past performance of beating the index by 2x?

NPAs Set to Rise Further with New RBI Rules(Chart Of The Day)

Feb 15, 2018

The RBI overhauls bad loan framework. Banks may come under additional pressure due to rising NPAs and increased provisioning.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

ELDER PHARMA SHARE PRICE


Sep 12, 2016 (Close)

TRACK ELDER PHARMA

  • Track your investment in ELDER PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

ELDER PHARMA 8-QTR ANALYSIS

COMPARE ELDER PHARMA WITH

MARKET STATS